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Abstract 
 
Background. Currently the majority of cancer deaths occur in low and middle-income countries 
where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for 
treatment and those who are insured are generally not covered for the full costs of treatment. This 
places a considerable burden on households if family members develop cancer. However, the actual 
cost of cancer treatment in Kenya is unknown. Such an analysis is essential to better allocate 
resources as Kenya strives towards universal healthcare.  Objectives. Evaluate the economic burden 
of treating cancer patients.  Method. Descriptive cross-sectional cost of illness study in the leading 
teaching and referral hospital in Kenya, with data collected from the hospital files of sampled adult 
patients for treatment during 2016.  Results: 412 patient files were reviewed, of which 63.4% (n=261) 
were female and 36.6% (n=151) male. Cost of cancer care is highly dependent on the modality. Most 
reviewed patients had surgery, chemotherapy and palliative care. The cost of cancer therapy varied 
with the type of cancer. Patients on chemotherapy alone cost an average of KES 138,207 (USD 
1364.3); while those treated with surgery cost an average of KES 128,207 (1265.6), and those on 
radiotherapy KES 119,036 (1175.1). Some patients had a combination of all three, costing on average 
KES 333,462 (3291.8) per patient during the year. Conclusion. The cost of cancer treatment in 
Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient 
admission. The greatest contributors are currently the cost of medicines and inpatient admissions. 
This pilot study can inform future initiatives among the government as well as private and public 
insurance companies to increase available resources, and better allocate available resources, to 
more effectively treat patients with cancer in Kenya. We will be monitoring developments and 
conducting further research.   
 
1. Introduction 
 
Cancer results in high morbidity and mortality (1). In 2012, it was estimated that approximately 14 
million new cases of cancer worldwide were diagnosed, with 8.2 million deaths due to cancer (2, 3). 
There were 8.8 million deaths due to cancer in 2015, with mortality due to cancer projected to rise to 
13 million deaths a year by 2030 due population growth and its ageing, increase in infection rates as 
well as an increase in unhealthy lifestyles known to cause cancer (3, 4). The majority of cancer 
deaths are now seen in middle and low-income countries (LMICs) (2, 5), with LMICs currently 
accounting for approximately 57% of cancer cases worldwide and approximately 65% of cancer 
deaths (3). Other authors have suggested up to 70% or more of the burden of cancer is now among 
LMICs (5, 6). Cancer mortality in LMICs is enhanced by late diagnosis as well as a lack of finances to 
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fund appropriate care (2, 3). Having said this, in higher income countries there appears limited 
correlation between resources spent and reduced mortality, with issues such as efficiency, patient 
centred care and timely treatment more important (7).  
 
In sub-Sahara Africa, the most common cancers affecting women are breast and cervical cancers 
with equal incidence, although cervical cancer leads to more deaths aided by infection; whilst among 
men, prostate and liver cancer are the most common and cause more deaths (2, 3). Prevalence rates 
are expected to more than double between 2008 and 2030, with the number of new patients 
developing cancer expected to rise to 1.6million by 2030 (5). In Kenya in 2012 there were 
approximately 41,000 new cases of cancer with 28,453 deaths (4, 8), making cancer the third highest 
cause of mortality after infectious and cardiovascular diseases at approximately 7% (8). Others 
though have suggested higher incidence rates in Kenya at approximately 82,000 new cancer patients 
annually, which may be due to improvements in disease detection and characterisation (6). 
 
Among women in Kenya, breast cancer (34 cases per 100,000) and cervical cancer (25 per 100,000) 
are the leading cancers, with prostate cancer (17 cases per 100,000) and esophageal cancer (9 
cases per 100,000) the leading cancers in men (6). There are though appreciable differences in 
incidence rates among the different ethnic groups in Kenya (9). For children, the most common 
cancers are leukemia, brain and other central nervous system cancer, and lymphomas. Childhood 
cancers accounted for 15% of cancer admissions at the leading tertiary hospital in Kenya with 
currently only 1 in 10 children surviving cancer in Kenya compared with rates of 7 in 10 or higher 
among developed countries (4, 6). However, these disparities in survival are likely to be multifactorial.  
 
The lack of adequate healthcare personnel and diagnostic equipment in Kenya has impacted on 
survival rates among diagnosed cancer patients. Currently there are only 4 radiation oncologists, 6 
medical oncologists and 4 paediatric oncologists located in the leading hospitals in Kenya, with 
ongoing concerns when machinery such as radiation equipment breaks down (6, 10). Some authors 
though have suggested higher figures, with a total of 22 oncologists currently in Kenya (4). These 
numbers will grow with already 5 new cancer centres being planned in Kenya including those outside 
Nairobi (4). 
 
There are also issues of affordability with high costs of care including physician visits, medicines, 
laboratory tests, surgery and other treatment modalities including radiation (11). The cost for one 
radiotherapy session at US$5 – 10 in the public hospital can be prohibitively expensive for 
disadvantaged Kenyans, who typically live on US$1 per day or less (10, 12, 13). The current 
estimated average costs of treating patients with cancer in Kenya at US$1,600 to $5,000 is a major 
concern as this would be unaffordable for most Kenyans (10), with only the wealthy able to fully afford 
treatment (10, 14). The type of insurance cover patients have is a major contributor to possible 
treatment approaches since even if patients can afford insurance, which is a minority, some insurance 
policies do not cover all cancer medicines and diagnostic tests with some limiting the number of 
chemotherapy courses a year (4, 14). Overall, treatment costs depend on many factors including the 
type of cancer, the type of treatment, the length of therapy and even the location of therapy. 
 
The cost of medicines is a major concern in LMICs countries including Kenya and worldwide as 
typically there are high co-payment levels and low incomes (5, 14-16). Prices of cancer medicines 
have risen up to ten fold during the past ten years in some countries despite often limited health gain 
(17-23), although this is not universal (24). Having said this, some pharmaceutical companies are 
giving up their patents for biological medicines to ease the patient burden as seen in India with 
trastuzumab (5). However, this is not universal among LMICs with for instance trastuzumab in 
Botswana currently only benefiting 3% of its cancer patients but consuming 43% of its entire cancer 
budget (4). Having said this, such practices may grow with estimates suggesting that the cost of 
production of even some newer cancer medicines may be as low as 1% of the selling price (25). In 
Kenya, chemotherapy typically costs between KES 6,000 (US$ 60) and KES600,000 (US$600) per 
treatment course in public hospitals depending on the cancer being treated (13); however, even these 
costs may be prohibitive to some patients, affecting their subsequent care (26). Costs to patients can 
be further increased with initial misdiagnosis (13).   
 
Since most patients in Kenya are not insured, and hence pay out-of-pocket for their care, this has 
important implications on timing when they seek treatment and the type of treatment they choose 
(27). As mentioned, current costs of cancer care impoverish many Kenyans as they struggle to 
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acquire the funds for treatment. Consequently, there is an urgent need to improve the knowledge of 
treatment costs to help guide patients with cancer and the government on potential ways forward as 
exact costs are currently unknown (28). Such information can better enable the government and 
donors to allocate more resources to cancer therapy if needed, and to patients to better understand 
possible costs. We believe such information will also help hospitals in Kenya to improve their waiver 
systems for selected cancer patients to ensure more accessible and affordable therapy to enhance 
equity and improve outcomes. This is important whilst Kenya strives towards universal healthcare. 
 
Consequently, the main objective of this pilot study is to start to quantify the cost of treatment of 
cancer patients in Kenyatta National Hospital (KNH), the leading referral hospital for cancer patients 
in Kenya. This includes direct medical costs including the costs of medicines, laboratory tests, 
radiation and surgery.   
 
2. Methodology  
 
2.1 Study Design, Duration and Site  
A descriptive cross-sectional study was carried out in the oncology unit at the Kenyatta National 
Hospital (KNH) between January and March 2017. The cost of illness study involved quantifying the 
direct medical costs involved in cancer treatment and care. The documented costs were those that 
the patients incurred during the time they visited the hospital in 2016. The actual time periods for 
different patients varied depending on the type and cycle of medication (chemotherapy) that they 
were on.  
 
Kenya National Guidelines on Cancer Management (2013) exist and current treatments are typically 
based on these guidelines (29). These guidelines have been adapted from the World Health 
Organisation (WHO) guidelines on cancer management. 
 
2.2 Study site  
The study was carried out at KNH, the largest referral and teaching hospital in Kenya. KNH treats 
various types of cancers affecting Kenyans in both the paediatric and adult settings. Moreover, most 
cancer patients in Kenya are currently referred to this hospital. The hospital has a specialized 
oncology unit, with most oncology specialists in Kenya currently working in this hospital. 
 
2.3 Study Population  
The study population were adults above 18 years of age being treated for different cancers at KNH in 
2016. The patients’ files were used to collect the data. Paediatric patients were excluded since 
patients were consulted in case additional data on resource use were required, and it was believed 
that it would be unfeasible to collect this information in children as frequently as paediatric patients 
would not have their parents or guardians present at the hospital at questioning. Consequently, it was 
predicted that missing cost information would introduce bias and best to avoid this in this pilot study. 
In addition, the vast majority of cancer cases in Kenya currently occur in adults (8).   
 
The sample size could not be easily calculated for the cross sectional study as there are no 
prevalence studies that have been undertaken for Nairobi since patients treated at KNH are sourced 
from across Kenya. However, from the KNH cancer registry of 2014-2016 (30), it was recorded that 
4,211 cancer patients were treated in that year. Using this estimate we decided to pick one out of 
every ten files from the registry, from which we obtained our pilot sample size of 412 patients after 
excluding those that did not meet the inclusion criteria. Sampling has also been undertaken in other 
LMIC countries to assess the extent of prescribing of chemotherapy agents for patients with cancer 
(31).   
 
According to the KNH Cancer registry, which was established in 2014, KNH attends to an average of 
over 550,000 outpatients annually, and over 80,000 inpatients per year. The registry estimates the 
total number of cancer patients between this period (2014-2016) at 10,335, with the majority being 
women at 6,279 and men at 4,056 (30). The most common cancer among females at KNH is cervical 
cancer (n=1800) followed by breast cancer (n=1500). The most common for men is oesophageal and 
prostate cancer in equal numbers (n=480 each). The leading cause of hospitalisation in KNH in the 
years 2015 and 2016 was cancer (30).   
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2.4 Data Collection  
The collection of data was undertaken with the aid of a data collection tool including the patients’ 
treatment history (Appendix A1). The data collected included patient demographics, medicines 
prescribed and their costs, cost of radiologic tests, costs of laboratory tests, any surgery and 
associated costs as well as the quantity and costs of any medical devices used.  
 
The information on the costs of medicines used during in-patient care were obtained from the 
expenditure and revenue collection unit for the oncology department of KNH. The costs of surgery in 
both the public and private sectors was based on current charges, with typically some subsidisation of 
costs in the public sector. These data were also collated from the revenue collection documents of the 
oncology department at KNH. Where information could not be obtained from patient records, for 
example, the costs of medical devices, patients were contacted and asked about these costs. The 
costs of radiotherapy and medical devices, as well as other pertinent additional costs, were obtained 
by history taking from the patients. This is because such costs could not be obtained from the KNH 
oncology department expenditure and revenue collection records. Where the services and medical 
devices could not be obtained from KNH, the patients procured these from other private facilities and 
paid for them out of pocket. This data was also recorded. 
 
We used a conversion rate of USD 1 = KES 101.3 (Central bank of Kenya - 
www.centralbank.go.ke/forex/). 
 
2.5 Data management and quality assurance  
The data were pretested in a pilot study of ten patients to ensure the feasibility of the study and its 
methodology as well as give a trend on the overall cost of therapy. All the data collected were 
recorded in a questionnaire. The data were cleaned and any errors or omissions corrected. The data 
was then transferred onto Excel spreadsheets, only accessed by the investigator and analysts. 
Backup of the data collected was undertaken every day. A qualified statistician was selected for the 
data analysis and quality assurance. 
 
Descriptive data analysis was undertaken and the results presented in figures, percentages and 
proportions. The data obtained was analyzed using STATA v13.0 (Stata Corporation, TX).  
 
2.6 Ethical Considerations  
The approval to carry out the study was sought from KNH-UON Ethics and Research Committee. 
Informed consent was sought from the Kenyatta Hospital Records management before conducting 
the study. In order to ensure confidentiality, serial numbers were used instead of patient names or in-
patient numbers or out-patient numbers so as to ensure the data remains confidential. All data 
collected was kept secure and could only be accessed by the investigator. 
 
3. Results 
 
Of the 412 patients reviewed, 261(63.4%) were female and the remaining 151 were male. A small 
percentage of reviewed patients treated for cancer in 2016 (16%) died of their disease; however, the 
majority of patients were still undergoing treatment at the time of the study.  
 
Of the reviewed patients, most of them were treated in the public wing (89.8%), with only a small 
percentage treated in the private wing of KNH. This reflects the fact that the public wing of KNH 
handles a considerable volume of patients versus the private wing. However, patients in the private 
wing pay more for their treatment.  
 
Surgery (25.4%) was the most frequently used treatment modality, followed by chemotherapy (24.6%) 
and palliative care (21.7%), with radiotherapy used in only a few cases (6.3%). A combination of any 
of the three modalities was seen in only a few cases, i.e.: of the 154 patients on chemotherapy: 
 96 had chemotherapy alone 
 36 had chemotherapy and surgery  
 14 had chemotherapy plus radiotherapy 
 8 had chemotherapy plus surgery plus radiotherapy 
 
Among the sampled patients, the most prevalent cancers among men were prostate cancer (9.7%, 
n=40) and colon cancer (2.9%, n=12). The most prevalent cancers among women were cervical 
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cancer (23.78%, n=98) and breast cancer (7.28%, n=30). There were also cancers that affected both 
men and women at approximately the same rate. These included oesophageal cancer, chronic 
myeloid lymphoma, colorectal cancer, pancreatic cancer and glioblastoma. This is included in figures 
1 to 4. 
 
Figure 1: Gender distribution of different types of cancer 
 
 
Figure 2: Gender distribution of different types of cancer (cont.) 
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Figure 3: Gender distribution of different types of cancer (cont.) 
 
 
Figure 4: Gender distribution of different types of cancer (cont.) 
 
 
 
 
The average cost of treatment for all the reviewed cases treated was KES 143,132 (1USD =101.3 
KES) (Table 1). The highest contributors to the cost of cancer therapy are the cost of medicines and 
inpatient admissions (Table 1). The cost of medical devices can also be high in view of equipment 
costs at a minimum of KES 5,500; however, this applied to only relatively few cases. Table 2 
documents the average costs incurred for the various modalities in treating patients with cancer in 
KNH in 2016. 
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Table 1 – Average cost of cancer care in KNH (2016) 
  
Variable  Observed 
cases 
Mean cost 
KES (USD) 
Std. Dev., 
KES (USD) 
Minimum cost 
KES (USD) 
Maximum cost 
KES (USD) 
Cost of drugs  401 32,311 (318.9) 55,974 (552.5) 25 (0.25) 579,500 
(5,720.6) 
Surgical 
procedures cost  
174 44,976 (443.9) 26,272 (259.3) 2,630 (26.0) 166,480 
(1,643.4) 
Radiology 
procedures cost  
298 17,197 (169.7) 24,102 (237.9) 700 (6.9) 131,300 
(1,296.1) 
Lab test cost  410 14,075 (138.9) 12,916 (127.5) 200 (1.9) 125,000 
(1,233.9) 
Cost Nursing 
and Drug 
Administration  
408 9,925 (97.9) 8890 (87.7) 2,174 (21.4) 91,990 (908.1) 
Consultation 
fee  
398 3,619 (35.7) 3,579 (35.3) 600 (5.9) 28,200 (278.3) 
Inpatient 
Admission cost  
412 27,875 ((275.1) 34,860 (344.1) 1,200 (11.8) 576,000 
(5,686.1) 
Cost of Medical 
Devices  
8 20,725 (204.5) 20,279 (200.1) 5,500 (54.2) 65,750 (649.1) 
 
Table 2 - Average Cost of Cancer Therapy in 2016 in KNH 
 
Variable  Number of cases Average Cost in KES 
(USD) 
Chemotherapy alone 96 138,207 (1364.3) 
Palliative care 88 98,931 (976.6) 
Surgery and radiotherapy 18 178,065 (1757.8) 
Surgery alone  96 128,207 (1265.6) 
Chemotherapy, radiotherapy and 
surgery 
8 333,463 (3291.8) 
Chemotherapy and radiotherapy 14 173,867 (1716.4) 
Chemotherapy and surgery 36 285,138 (2814.8) 
Radiotherapy 26 119,036 (1175.1) 
Diagnostic fees and tests 12 48,273 (476.5) 
 
Surgery is an important mode of treatment of cancer used, with higher costs when combined with 
other modes of therapy. The only surgical procedures carried out in the selected cohort of patients 
during the observation period were hysterectomy, radical mastectomy, laparotomy, colectomy and 
thyroidectomy. For colon cancer patients, a colectomy was performed. No surgery was undertaken for 
patients with prostate cancer during the observation period. Some cervical cancer patients (n=10) 
also underwent a laparotomy for diagnostic purposes. Overall, the most expensive procedures were 
surgery combined with radiotherapy and chemotherapy (Table 2). Table 3 depicts the current costs 
(charges) for common surgical procedures in both the public and private sectors in Kenya in 2017. 
 
Table 3: Cost of commonly used surgeries during therapy in KNH in 2017  
 
Type of Surgery 
 
Public sector charges KES, 
(USD) 
Private sector charges KES, 
(USD) 
Hysterectomy  50,000 (493.6) 50,000 (493.6) 
Radical mastectomy  27,000 (266.5) 40,500 (399.8) 
Laparotomy  36,000 (355.4) 54,000 (533.1) 
Colectomy  36,500 (360.3) 54,750 (540.5) 
Thyroidectomy  27,000 (266.5) 40,500 (399.8) 
 
The cost for using the theatre and consumables during the surgery was charged separately. The 
theatre charge was KES 2,000, while the theatre consumables vary with the patient. 
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Radiological procedures vary from those used for diagnosis and monitoring to the use of radiotherapy 
as part of treatment. Radiotherapy as part of the treatment regimen is the most expensive, costing an 
average of KES 31,769 per patient, with the cost of radiotherapy appreciably increasing when used 
with other treatment modalities (Table 3).  Table 4 contains the cost of common laboratory tests 
undertaken during treatment in 2016. 
 
Table 4: Cost of Common Laboratory Tests offered during therapy in 2016 
 
Laboratory Test  Cost per test, KES (USD) 
Full Haemogram  500 (4.9) 
Liver Function Test  900 (8.9) 
Renal Function Test  1,300 (12.8) 
Thyroid Function Test  900 (8.9) 
Urinalysis  700 (6.9) 
Blood biochemistry  700 (6.9) 
Lipid profile  900 (8.9) 
HER-2 test  900 (8.9) 
Histology  1,200 (11.8) 
 
The cost of nursing includes the cost of catheterization, nebulization, wound dressing, drug infusion 
among others. The cost of such services depends on the type of admission the patient used (public or 
private ward admission).  
 
A number of drug regimens are used for various cancers based principally on current national 
guidelines (29). The most expensive drug regimen used during the observational period was 
fluorouracil and actinomycin D costing KES 2,224,990 per patient (Table 5), while the cheapest was 
fluorouracil alone which cost KES 30,580. 
 
Table 5 – Average cost of chemotherapy regimens in 2016 
.  
Chemotherapy regimen No of 
patients 
Mean KES, (USD) 
ABVD (Adriamycin, Bleomycin, Vinblastine, 
Dacarbazine) 
8 110,919 (1,094.6) 
AC (Adriamycin, Cyclophosphamide) 7 140,255 (1,384.6) 
ACH (Adjuvant chemotherapy) 1 861,080 (8,500.3) 
ATMZL (Adriamycin, Temozolomide) 2 307,744 (3,037.9) 
Bendamustine + Chlorambucil 1 66,260 (654.1) 
Bleomycin, Etoposide, Cisplatin 6 435,191 (4,296.1) 
Cyclophosphamide, Adriamycin 6 145,897 (1,440.2) 
Cyclophosphamide, Adriamycin, Vincristine 1 113,945 (1,124.8) 
Cyclophosphamide, Adriamycin, Vincristine, 
Prednisone 
1 111,990 (1,105.5) 
Cisplatin, Gemcitabine 1 117,223 (1,157.2) 
Chlorambucil 1 59,240 (584.8) 
Cisplatin 1 135,945 (1,342.0) 
COP (Cyclophosphamide, Vincristine, 
Prednisone) + Chlorambucil 
1 209,760 (2,070.7) 
Fluorouracil, Actinomycin D 1 2,224,990 (21964.4) 
 
The cost of treating each type of cancer during 2016 depends on the type of cancer, its stage and 
treatment approaches. The most expensive cancer treated was a refractory trophoblastic tumour 
(KES 2,224,990), followed by subglottic granuloma which costed KES 486,876 per patient whilst the 
cheapest included renal carcinoma which cost KES 68,017 (Figure 5). Table A2 in the Appendix 
contains more details including the number of patients with the different cancers and the mean cost in 
USD. 
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Figure 5:  Average cost of treating different types of cancer (KES) 
 
 
  
The cost of treating patients with cancer during 2016 was appreciably higher in the private sector than 
in the public sector for the same mode of therapy, with variations ranging from KES 15,369 to KES 
602,991 depending on the treatment involved (Table 6). 
 
Table 6: Cost variations in KES between the private and public sectors (USD in parenthesis) 
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Mean cost (KES)
Variable Group Obs. Mean Std. Err. Std. Dev. [95% Conf. Interval] df P 
value 
Chemotherapy Public  89 125685 
(1240.7) 
8737 
(86.2) 
82424 
(813.7) 
108323 
(1069.3) 
143048 
(1412.1) 
93 0.0014 
Private  6 337085 
(3327.6) 
228328 
(2254.0) 
559287 
(5521.1) 
-249851  
(-2466.4) 
924021 
(9121.6) 
Combined  95 139037 
(1372.5) 
16438 
(162.3) 
160222 
(1581.7) 
106398 
(1050.3) 
171676 
(1694.7) 
Difference  
 
-211400  
(-2086.9) 
64308 
(634.8) 
 
-339103   
(-3347.5) 
-83697 
(-826.2) 
Palliative care  Public  73 94867 
(936.5) 
13392 
(132.2) 
114423 
(1129.5) 
68170 
(673.0) 
121564 
(1200.0) 
86 0.4417 
Private  15 118708 
(1171.8) 
18953 
(187.1) 
73406 
(724.6) 
78058 
(770.6) 
159359 
(1573.1) 
Combined  88 98931 
(976.6) 
11572 
(114.2) 
108553 
(1071.6) 
75931 
(749.6) 
121931 
(1203.7) 
Difference 
 
-23841    
(-235.4) 
30845 
(304.5) 
 
-85159    
(-840.7) 
37476 
(370.0) 
Surgery and 
Radiotherapy 
Public  17 177211 
(1749.4) 
23484 
(231.8) 
96828 
(955.9) 
127426 
(1257.9) 
226995 
(2240.8) 
  
Private  1 192580 
(1901.1) 
 
   
Combined  18 178065 
(1757.8) 
 
   
Difference  
 
-15369     
(-151.7) 
 
   
Surgery  Public  84 123721 
(1221.3) 
9262 
(91.4) 
84890 
(838.0) 
105299 
(1039.5) 
142144 
(1403.2) 
93 0.1344 
 
Private  11 164826 
(1627.1) 
25608 
(252.8) 
84934 
(838.4) 
107766 
(1063.8) 
221885 
(2190.4) 
Combined  95 128481 
(1268.3) 
8769 
(86.6) 
85471 
(843.7) 
111070 
(1096.4) 
145892 
(1440.2) 
Difference  
 
-41104    
(-405.8) 
27221 
(268.7) 
 
-95160    
(-939.4) 
12952 
(127.9) 
Public  7 258089 
(2547.8) 
42036 
(415.0) 
111216 
(1097.9) 
155231 
(1532.4) 
360947 
(3563.1) 
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4. Discussion 
 
Out of the 412 reviewed cancer cases 63% were female and 37% were male. This corresponds to a 
study by Korir et al (32) which reported a higher incidence of cancer in females than males in Kenya. 
The cancer rate for women is 231 per 100, 000 people while the rate for men is 161 per 100,000 
people in an age standardized incidence rate study (32). Our findings also corroborate the data on the 
Kenyatta National Hospital Registry (2014-2016) which reported that there were more females than 
males currently being treated for cancer in Kenya (30). In this period, cancer remained the main 
cause for hospitalisation in KNH. However, different from a middle income country such as Iran where 
more men than women are receiving chemotherapy (31). 
 
In East Africa, 116,800 men and 170,500 women were diagnosed with cancer in 2012. Of all the 
cases diagnosed that year, 92,500 men died due to cancer and 116,500 women died as a result of 
cancer. Statistics therefore suggests that cancer morbidity and mortality effects women more than 
men (33). This could be attributed to the health seeking behaviour of women, who are more likely to 
seek treatment than men, as well as perhaps greater prevalence of overweight and obesity as seen 
for instance in other African countries (34). Women are also more likely to be on hormonal 
contraceptives, which could be an etiological factor in promoting the growth of hormone dependent 
cancers, although studies on their role are conflicting (35-38).  
 
The cost of treating cancer in our study depended on the type of cancer, the chemotherapy regimen 
prescribed, the radiotherapy sessions prescribed as well as the numerous laboratory and radiologic 
tests that the patients should undergo during diagnosis and treatment. Regarding the chemotherapy 
regimens used, whilst cyclophosphamide was being administered in a number of patients (Table 5), 
there appeared to more limited use of capecitabine, cisplatin, docetaxel, doxorubicin, fluorouracil, 
imatinib, or oxaliplatin compared with other LMIC countries (31, 39). Overall, chemotherapy is the key 
driver of treatment costs, reflected in other studies (5, 17, 40). Even though laboratory and radiologic 
investigations are important in the diagnosis and management of various cancers, there are concerns 
that unnecessary use will increase health care costs and expose patients to unnecessary radiation 
(41). This is an area we will be researching further in the future along with researching variations in 
the cost of radiologic and laboratory examinations between sectors to guide future policy. Other 
authors have also shown that government and teaching hospitals charged less than other hospitals 
for blood tests (42). 
 
Overall, the cost of treatment of cancer patients is prohibitively high for most patients in Kenya. Kenya 
is a low income country, where four out of ten people live below the poverty line, according to the 
World Bank. Currently, the Kenyan healthcare system relies heavily on out of pocket payments for 
healthcare (14), although there are moves towards universal healthcare (4). For this reason, patients 
may not be able to afford expensive chemotherapy, surgical and radiotherapy procedures and may 
default on their treatment, negatively impacting on their outcome.  However, The Ministry of Health is 
currently underfunded and cannot pay for the costs of all patients with cancer although there are 
ongoing moves to improve the availability of facilities and personnel (4). The National Health 
Insurance Fund (NHIF) pays for some costs of patients, but only caters for inpatient hospital stay. 
Some hospitals, including Kenyatta National Hospital, have adopted a waiver system to cover the 
costs of care for extremely poor patients. This still has challenges though as the hospitals are not able 
to cover the costs of all patients (43). In addition, there are problems applying the waiver system for 
cancer patients since the costs of treating these patients can be very high. This calls for a revision in 
healthcare financing policies in Kenya to meet the WHO standards for equity in healthcare (14) as 
well as Sustainable Development Goal 3.4 (4). This also calls for initiatives to obtain low prices for 
cancer medicines in Kenya, building on current access initiatives in other disease areas (44), as many 
patents for standard cancer medicines are now expired, with increasing availability of biosimilars, 
although there can be concerns with quality of generics in LMICs (45).  
 
Chemotherapy
, surgery and 
radiotherapy 
Private  1 861080 
(8500.3) 
    
  
Combined  8 333463 
(3291.8) 
    
  
Difference    -602991  
(-5952.5) 
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We are aware that we only carried out this pilot study in one hospital (KNH). However, this is the 
national referral hospital treating an appreciable number of patients with cancer in Kenya. We also 
only used patients’ notes for the analysis with the limitations this imposes on content and accuracy. 
However, such methods are routinely used to collect costing data in the absence of electronic medical 
records. In addition, we are aware that there were only a limited number of patients with some 
cancers making statistical analysis difficult to interpret and we only included costs for one year. We 
also could not adequately calculate the sample size due to absence of cancer prevalence studies.  
Despite these limitations, we believe our findings are robust and provide a basis for assessing the 
costs of cancer care in Kenya in the future, which we and others can build upon this in future research 
including much larger patient samples and duration for the different cancer types.   
 
5. Conclusion 
 
The cost of cancer treatment in Kenya varies by type of cancer, the modality, cost of medicines and 
the type of inpatient admission. However, the cost of medicines and inpatient admissions are currently 
the greatest cost components in the treatment of patients with cancer in Kenya.  
 
It is anticipated that this study will provide a platform to inform future initiatives from the government 
as well as both private and public insurance companies in Kenya to increase resource availability, and 
better allocate available resources, to more effectively treat patients with cancer in Kenya given the 
current high burden for patients. In addition, provide a basis for future research efforts. Greater 
availability of generic anticancer medicines as well as biosimilars should help in the future as Kenya 
strives towards universal access. 
 
6. Recommendations  
 
The cost of cancer therapy is currently high in Kenya with respect to average salaries. Consequently, 
all parties involved should play their role in reducing the prevalence and burden to patients. This 
includes instigating programmes to reduce behaviours that increase the risk of cancer. In view of this, 
we believe patients should be encouraged to go for regular check-ups to hasten early diagnosis and 
monitor progression, as well as be given advice and encouragement to alter their lifestyles to reduce 
their potential for developing cancer. Lifestyle changes include dietary modifications, exercise, and 
weight loss where pertinent.  
 
We also believe for those patients with insurance, insurance companies should allocate more 
resources to cancer therapy to ease the burden for their clients. The National Health Insurance Fund 
(NHIF), which is public insurance offered by the Kenyan government, should also increase its 
comprehensive cover for cancer patients in all settings building on current initiatives.  Furthermore, 
we believe hospitals and donor companies should increase their waiver for cancer patients who are 
struggling to fund their care to improve future care. Lastly, the Ministry of Health should explore 
potential access schemes for patients with cancer, building on initiatives in other disease areas. We 
will be monitoring this development. 
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Appendix 
 
Appendix 1 - Data Collection Tool  
 
Section 1: PATIENT DEMOGRAPHICS  
Patient Serial Number______________ Age____ Sex_______  
Date of Admission_______________________ Setting: □ In patient □ Out patient  
Date of Data Collection___________________  
Patient area of Residence__________________  
Diagnosis____________________________________________________________________  
 
Section 2: DIRECT HEALTHCARE COSTS  
A) Cost of Drugs (KES)  
Cancer Chemotherapy  Drugs for Adverse effects  Drugs for Co-morbidities  
Name  Cost (KES)  Name  Cost(KES)  Name  Costs(KES)  
1  
2  
3  
4  
5  
6  
7  
 
 
B) Cost of Surgical Procedures  
Name of Procedure  Cost(KES)  
1  
2  
3  
4  
5  
 
Done in KNH □Yes □No  
If no state where___________________ 
 
C) Cost of Radiology Procedures  
Name of Procedure  Cost(KES)  
1 Radiotherapy 
2 X-Rays 
3 CT-Scan 
4 MRI 
5 Others 
 
Done in KNH □Yes □No  
If no state where___________________ 
 
D) Cost of Laboratory tests 
Name of Test  Cost(KES)  
1  
2  
3  
4 
5  
 
Done in KNH □Yes □No  
If no state where___________________ 
 
E) Cost of Nursing and Drug Administration  
Name  Cost(KES)  
1  
15 
 
2  
3  
4 
5  
 
F) Consultation Fee 
Date/ Type of 
Consult 
Cost(KES)  
1  
2  
3  
4 
5  
 
G) Inpatient Admission Costs 
Type  Cost 
(unit/day) 
Total Cost 
(KES)  
1 
2 
3 
 
H) Cost of Medical Devices 
Equipment Cost(KES)  
1  
2  
3  
4 
5  
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Appendix A2:  Average Cost of treating different types of cancer 
 
Type of cancer Number of patients Mean cost (KES) (USD in brackets) 
Cervical Carcinoma 91 119323 (1177.9) 
Endometrial Carcinoma 14 164550 (1624.4) 
Ovarian Carcinoma 28 224581 (2217.0) 
Penile Carcinoma 9 108408 (1070.2) 
Oesophagael Carcinoma 16 87804 (866.8) 
Prostate Carcinoma 34 113462 (1120.1) 
Axillary Sarcoma 1 113945 (1124.8) 
Cholangiocarcinoma 8 159687 (1576.4) 
Bladder Carcinoma 13 116380 (1148.9) 
Bone cancer 1 128288 (1266.4) 
Glioblastoma Multiform 6 82525 (814.7) 
Breast Carcinoma 28 141251 (1394.4) 
Bronchoccular adenocarcinoma 2 130683 (1290.1) 
Cancer of the Larynx 5 125291 (1236.8) 
Rectal Cancer 10 145627 (1437.6) 
Cancer of Ileum 1 224820 (2219.3) 
Cancer of Palate 1 99920 (986.4) 
Oropharyngeal cancer 3 91344 (901.7) 
Cancer of the vulva 6 254011 (2507.5) 
Choriocarcinoma 3 82946 (818.8) 
Chronic Lymphocytic leukemia 4 117936 (1164.2) 
Chronic Myeloid Leukemia 10 69496 (686.0) 
Colon Cancer 15 216395 (2136.2) 
Colorectal Cancer 4 176471 (1742.1) 
Testicular Cancer 1 91090 (899.2) 
Follicular Thyroid Carcinoma 15 136017 (1342.7) 
Gall Bladder Cancer 2 41323 (407.9) 
Hodgkins Lymphoma 7 103934 (1026.0) 
Lip Cancer 1 98952 (976.8) 
Liver Cancer 1 132038 (1303.4) 
Lung Mass to Colon Cancer 1 182111 (1797.7) 
Malignant Melanoma 2 75346 (743.8) 
Phaeochromocytoma 4 213564 (2108.2) 
Multiple Myeloma 14 149226 (1473.1) 
Non-Hodgkin Lymphoma 2 106298 (1049.3) 
Oral Squamous Cell Carcinoma 1 444388 (4386.9) 
Pancreatic Cancer 10 126012 (1244.0) 
Parotid Cancer 4 166130 (1640.0) 
Renal Carcinoma 1 68017 (671.4) 
Rhabdomyosarcoma 1 80170 (791.4) 
Gastric Adenocarcinoma 9 355291 (3507.3) 
Subglottic Granuloma 1 486876 (4806.3) 
T cell Lymphoma 1 111990 (1105.5) 
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Refractory Trophoblastic Tumour 1 2224990 (21964.4) 
 
 
